Drug intelligence / Profile preview

gsk3b siRNA

Development stage
Preclinical
Lead developer
Kanazawa University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

GSK3β siRNA is a small interfering RNA designed to silence the expression of glycogen synthase kinase 3 beta (GSK3β). GSK3β is a serine/threonine kinase that plays a critical role in various signaling pathways, including Wnt/β-catenin and insulin signaling. In many cancers, including glioblastoma, GSK3β is overexpressed and contributes to tumor cell survival, proliferation, and resistance to apoptosis by modulating the activity of p53, p21, and Rb. By utilizing the RNA interference (RNAi) pathway, GSK3β siRNA specifically targets and facilitates the degradation of GSK3β mRNA, leading to a reduction in protein levels. This inhibition has been shown to induce apoptosis and sensitize cancer cells to radiation and chemotherapy in preclinical models. Research conducted at Kanazawa University has highlighted its potential as a therapeutic strategy for refractory brain tumors.

Other names
GSK3B siRNAGSK-3B siRNAGSK 3B siRNAGSK3β siRNAglycogen synthase kinase 3 beta siRNA
02

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on gsk3b siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gsk3b siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call